We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.46B
AUM Growth
-$440K
Cap. Flow
-$163M
Cap. Flow %
-11.2%
Top 10 Hldgs %
60.09%
Holding
84
New
10
Increased
23
Reduced
32
Closed
17

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$24.1M
2
ZIMV
ZimVie
ZIMV
+$23.4M
3
FTRE icon
Fortrea Holdings
FTRE
+$10.8M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$10.2M
5
BHC icon
Bausch Health
BHC
+$10.1M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$44.6M
2
UTHR icon
United Therapeutics
UTHR
+$35.3M
3
NTRA icon
Natera
NTRA
+$34.8M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$26M
5
NVO
Novo Nordisk
NVO
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 89.3%
2 Miscellaneous 10.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GSK icon
1
GSK
GSK
$102B
$166M 11.36%
4,057,206
+589,126
+17% +$24.1M
QQQ icon
2
PUT
Invesco QQQ Trust
QQQ
$489B
$122M 8.34%
249,600
-36,000
-13% -$17M
NTRA icon
3
Natera
NTRA
$47B
$110M 7.57%
870,193
-303,301
-26% -$34.8M
VERA icon
4
Vera Therapeutics
VERA
$2.46B
$90.6M 6.21%
2,050,157
+6,943
+0.3% +$263K
INSM icon
5
Insmed
INSM
$25.9B
$79.5M 5.45%
1,089,404
-66,184
-6% -$4.88M
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$1.74B
$79M 5.41%
4,105,313
+491,682
+14% +$10.2M
RVTY icon
7
Revvity
RVTY
$14.4B
$60M 4.11%
469,692
+18,110
+4% +$2.13M
INSP icon
8
Inspire Medical Systems
INSP
$1.78B
$58.3M 3.99%
276,270
-256,741
-48% -$44.6M
TEVA icon
9
Teva Pharmaceuticals
TEVA
$42.5B
$58.3M 3.99%
3,234,638
-1,485,822
-31% -$26M
CYH icon
10
Community Health Systems
CYH
$413M
$53.3M 3.65%
8,776,455
+738,985
+9% +$3.62M
TECH icon
11
Bio-Techne
TECH
$11.3B
$53M 3.63%
663,573
+120,529
+22% +$9.06M
HCA icon
12
HCA Healthcare
HCA
$90.5B
$52.5M 3.59%
129,084
-6,396
-5% -$2.34M
UTHR icon
13
United Therapeutics
UTHR
$22.1B
$46.9M 3.21%
130,949
-104,402
-44% -$35.3M
SPY icon
14
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$34.4M 2.36%
60,000
+29,200
+95% +$16.1M
ZIMV
15
DELISTED
ZimVie
ZIMV
$32.9M 2.25%
2,070,780
+1,303,121
+170% +$23.4M
HQY icon
16
HealthEquity
HQY
$7.97B
$26.1M 1.79%
319,078
-94,453
-23% -$7.29M
RGEN icon
17
Repligen
RGEN
$9.95B
$24.3M 1.67%
163,593
-30,698
-16% -$4.4M
VTRS icon
18
Viatris
VTRS
$18.8B
$20M 1.37%
1,726,354
+397,072
+30% +$4.58M
PTGX icon
19
Protagonist Therapeutics
PTGX
$9.34B
$20M 1.37%
445,204
-60,632
-12% -$2.45M
CLDX icon
20
Celldex Therapeutics
CLDX
$3.07B
$19.2M 1.32%
564,902
-68,113
-11% -$2.6M
IONS icon
21
Ionis Pharmaceuticals
IONS
$10.1B
$18.9M 1.29%
471,355
+14,474
+3% +$673K
VRDN icon
22
Viridian Therapeutics
VRDN
$2.61B
$15.7M 1.08%
691,232
+123,745
+22% +$2.02M
MNKD icon
23
MannKind Corp
MNKD
$1.27B
$12.5M 0.86%
1,992,504
-264,448
-12% -$1.52M
BHC icon
24
Bausch Health
BHC
$2.36B
$12.5M 0.86%
+1,530,914
New +$10.1M
TVTX icon
25
Travere Therapeutics
TVTX
$6.19B
$12.2M 0.83%
869,913
-221,252
-20% -$2.31M
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Eversept Partners held 84 positions worth $1.46B, down 0.03% from $1.46B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Eversept Partners withdrew a net $163M in Q3 2024, closing 17 positions and reducing 32 holdings. Its most notable exit was Novo Nordisk, an estimated $21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 89% a quarter earlier, followed by Miscellaneous.

Against the trend, Eversept Partners opened a new position in Fortrea Holdings worth $9.16M.

  • Eversept Partners's largest Q3 2024 buy was Fortrea Holdings: 457,967 shares worth $9.16M.
  • Eversept Partners added most to GSK in Q3 2024, an estimated $24.1M increase.
  • Eversept Partners's biggest Q3 2024 reduction was Inspire Medical Systems, cutting an estimated $44.6M.
  • Eversept Partners fully exited Novo Nordisk in Q3 2024, selling an estimated $21M.
  • Eversept Partners's ten largest holdings make up 60% of its $1.46B portfolio in Q3 2024.
  • Eversept Partners opened 10 new positions and closed 17 in Q3 2024.
  • Eversept Partners's portfolio value fell 0.03% quarter-over-quarter to $1.46B.

Based on Eversept Partners's 13F filing for Q3 2024, filed 14 Nov 2024.